Inspection Record

Verity Pharmaceuticals Inc. — Health Canada Inspection Findings

Health CanadaInspected 2023-12-19 7 findingsQuality unit oversightComplaint and recall handlingStability and storageDeviation, CAPA, and investigationRegulatory reporting and change controlOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The annual product quality review procedure was inadequate.

2Complaint and recall handling

The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.

3Stability and storage

The ongoing stability program for a drug was inadequate.

4Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

5Complaint and recall handling

The written procedures for recalls were inadequate.

6Regulatory reporting and change control

The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.

7Other quality system

The handling of standard operating procedures for good manufacturing practices was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2023-12-19. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Verity Pharmaceuticals Inc. company profile — full history Health Canada documents, 2023 Go to Findings search